Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT ID: NCT01139333
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
52 participants
OBSERVATIONAL
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is studying blood and tumor tissue samples from young patients with acute myeloid leukemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia
NCT01139931
Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia
NCT01653613
Studying DNA in Blood and Bone Marrow Samples From Young Patients With Acute Lymphoblastic Leukemia
NCT01016379
Studying Gene Expression in Tissue Samples From Patients With Acute Myeloid Leukemia
NCT01057095
Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
NCT01520246
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To evaluate Mer and Axl expression in samples from pediatric patients with acute myeloid leukemia (AML).
* To determine if abnormal expression of Mer and Axl is associated with poor clinical characteristics (e.g., induction failure or relapse) of AML in these patients.
OUTLINE: This is a multicenter study.
Archived samples from pediatric patients with acute myeloid leukemia are analyzed for Mer and Axl expression by flow cytometry and western blot assays.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gene expression analysis
western blotting
flow cytometry
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute myeloid leukemia
* Children Oncology Group (COG) patient samples
PATIENT CHARACTERISTICS:
* Available clinical data
PRIOR CONCURRENT THERAPY:
* Not specified
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kristen M. Eisenman, MD
Role: PRINCIPAL_INVESTIGATOR
University of Colorado, Denver
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AAML10B4
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000671452
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02222
Identifier Type: REGISTRY
Identifier Source: secondary_id
AAML10B4
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.